Search Results - "Zamarin, D."

Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000–2013 by Oseledchyk, A., Leitao, M.M., Konner, J., O’Cearbhaill, R.E., Zamarin, D., Sonoda, Y., Gardner, G.J., Long Roche, K., Aghajanian, C.A., Grisham, R.N., Brown, C.L., Snyder, A., Chi, D.S., Soslow, R.A., Abu-Rustum, N.R., Zivanovic, O.

“…We sought to evaluate the impact of adjuvant chemotherapy on overall survival (OS) in patients with stage I endometrioid epithelial ovarian cancer (EEOC) or…”
Get full text

Genetically engineered Newcastle disease virus for malignant melanoma therapy by Zamarin, D, Vigil, A, Kelly, K, García-Sastre, A, Fong, Y

“…Despite the advances in cancer therapies in the past century, malignant melanoma continues to present a significant clinical challenge due to lack of…”
Get full text

Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation by Zamarin, D, Giralt, S, Landau, H, Lendvai, N, Lesokhin, A, Chung, D, Koehne, G, Chimento, D, Devlin, S M, Riedel, E, Bhutani, M, Babu, D, Hassoun, H

“…Auto-SCT (ASCT) is widely used in first-line treatment of multiple myeloma (MM). However, most patients eventually relapse or have progression of disease…”
Get full text

Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance by Zamarin, D, Devlin, S M, Arcila, M E, Landau, H, Lesokhin, A, Lendvai, N, Chung, D J, Chimento, D, Weltz, J, Babu, D, Giralt, S, Hassoun, H

Get full text

Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines by Dai, M.-H., Zamarin, D., Gao, S. P., Chou, T.-C., Gonzalez, L., Lin, S.-F., Fong, Y.

“…Background: Despite much research in chemotherapy and radiotherapy, pancreatic adenocarcinoma remains a fatal disease, highly resistant to all treatment…”
Get full text

Influenza A viruses with truncated NS1 as modified live virus vaccines: Pilot studies of safety and efficacy in horses by Chambers, T. M., Quinlivan, M., Sturgill, T., Cullinane, A., Horohov, D. W., Zamarin, D., Arkins, S., García-Sastre, A., Palese, P.

“…Summary Reasons for performing study: Three previously described NS1 mutant equine influenza viruses encoding carboxyterminally truncated NS1 proteins are…”
Get full text

Differential IL-10R1 Expression Plays a Critical Role in IL-10-Mediated Immune Regulation by Ding, Yaozhong, Qin, Lihui, Zamarin, Dmitriy, Kotenko, Sergei V, Pestka, Sidney, Moore, Kevin W, Bromberg, Jonathan S

“…In this study, we characterized the differential receptor-binding specificity, affinity, and Janus kinase-STAT activation of cellular IL-10 (cIL-10) compared…”
Get full text

Image Guided Brachytherapy Quality Assurance on NRG GY017, an NRG Oncology Clinical Trial Investigating the Sequencing of Immunotherapy and Chemoradiation for Locally Advanced Cervical Cancer by Kim, H., Deng, W., Nguyen, H., Leif, J.L., McNulty, S., Zamarin, D., Chino, J.P., Ghamande, S., Ferguson, C.L., Mell, L.K., Holman, L.L., Mathews, C., O’malley, D., Olawaiye, A., Hopp, E., Leath, C., Aghajanian, C., Schilder, R., Xiao, Y., Mayadev, J.S.

“…NRG GY-017 is a randomized Phase I trial of the anti-PD-L1 antibody atezolizumab administered neoadjuvantly and concurrently (Arm A) or concurrently with chemo…”
Get full text

A phase II trial of TPIV200 (a polypeptide vaccine against folate receptor alpha) plus durvalumab (anti-PD-L1 antibody) in patients with platinum-resistant ovarian cancer by Yeku, O., Zamarin, D., Gallagher, J., Aghajanian, C.A., Konner, J.

Get full text

Association of CD8+ T cell gene expression signatures with outcomes in the distinct molecular subtypes of endometrial cancer by Dessources, K., Ferrando, L., Riaz, N., Reis-Filho, J., Zamarin, D., Weigelt, B.

Get full text

Systemic and intratumoral stress responses to primary debulking surgery in patients with epithelial ovarian cancer by Moukarzel, L.A., Ferrando, L., Bykov, Y., Stylianou, A., LaVigne, K., Roche, K. Long, Weigelt, B., Zamarin, D.

Get full text

Genomic analysis of high-grade serous ovarian cancer in young and older women by Filippova, O.T., Selenica, P., Lee, S.S., Pei, X., Riaz, N., Reis-Filho, J., Zamarin, D., Weigelt, B.

Get full text

Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent high-grade and low-grade serous ovarian cancer by Grisham, R.N., Giri, D.D., McDonnell, A., Iasonos, A., Zhou, Q., Li, K., Girshman, J., O'Cearbhaill, R.E., Zamarin, D., Aghajanian, C.

Get full text

Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer by Liu, Y.L., Emengo, V.N., Friedman, C.F., Konner, J., O'Cearbhaill, R.E., Aghajanian, C.A., Zamarin, D.

Get full text

Role of serum CA-125 in monitoring ovarian cancer patients on checkpoint blockade immunotherapy by Boland, J., Zhou, Q., Iasonos, A., Sabbatini, P., Aghajanian, C.A., Zamarin, D., Cadoo, K.A.

Get full text

Immune-reactive microenvironment of small cell carcinoma of the ovary, hypercalcemic type provides a rationale for evaluating immunotherapies to treat this malignancy by Jelinic, P., Ricca, J., Van Oudenhove, E., Olvera, N., Merghoub, T., Levine, D.A., Zamarin, D.

Get full text

Immune and genomic profiling of small cell carcinomas of the ovary hypercalcemic type by Dessources, K., Holland, A., Liu, J.D., Lee, S.S., Selenica, P., Wu, M., Stylianou, A., Reis-Filho, J., Hyman, D.M., Hollmann, T.J., Zamarin, D., Weigelt, B.

Get full text

Predictors of early treatment discontinuation in ovarian cancer patients on checkpoint blockade immunotherapy by Boland, J.L., Martin, M., Zecca, N., Iasonos, A., Zhou, Q., Aghajanian, C.A., Sabbatini, P., Cadoo, K.A., Zamarin, D.

Get full text

Compositional and architectural characterization of high-grade serous ovarian carcinomas using single cell technologies and multiplex microscopy by Kim, S.H., Holland, A., Jimenez-Sanchez, A., Bykov, Y., Fromme, R.M., Stylianou, A., Walther, T., Liu, C., Leitao, M.M., Zivanovic, O., Sonoda, Y., Chi, D.S., Abu-Rustum, N.R., Mazutis, L., Plitas, G., Hollmann, T.J., Weigelt, B., Pe'er, D., Zamarin, D.

Get full text

A phase II study of atezolizumab in combination with bevacizumab in patients with recurrent, persistent or metastatic cervical cancer by Friedman, C.F., Snyder, A., Sharon, E., De Meritens, A. Buckley, Cantrell, L.A., Corr, B.R., Konner, J., Konstantinopoulos, P.A., Soldan, K., Aghajanian, C.A., Zamarin, D.

Get full text